v3.26.1
Description of Business and Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 4 Months Ended 6 Months Ended
Sep. 12, 2025
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
$ / shares
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
Jun. 30, 2026
USD ($)
Segment
$ / shares
shares
Jun. 30, 2025
USD ($)
Subsidiary, Sale of Stock [Line Items]                
Research and development expense           $ 2,983,773    
Net loss   $ 3,290,970 $ 3,150,228 $ 60,346 $ 137,583   $ 6,441,198 $ 197,929
Cas in operating activities             2,034,671 $ 440,029
Cash and cash equivalents   2,938,463         2,938,463  
Accumulated deficit   11,288,753       4,847,555 11,288,753  
Prepaid research and development   1,819,177       $ 6,166,294 1,819,177  
FDIC insured amount   $ 250,000         $ 250,000  
Common stock, par value | $ / shares   $ 0.0001       $ 0.0001 $ 0.0001  
Number of operating segment | Segment             1  
Number of reportable segment | Segment             1  
IPO [Member]                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued, shares | shares             3,750,000  
Common stock, par value | $ / shares   0.0001         $ 0.0001  
Sale of stock price per share | $ / shares   $ 4.00         $ 4.00  
Gross proceeds             $ 15,000,000.0  
Net proceeds             2,120,000  
Underwriting discounts and commissions             1,410,000  
Other offering related expenses   $ 710,000         710,000  
Net proceeds             $ 13,240,000  
Over-Allotment Option [Member]                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued, shares | shares 562,500              
Sale of stock price per share | $ / shares $ 4.00              
Gross proceeds $ 2,250,000              
Underwriting discounts and commissions 180,000              
Net proceeds $ 2,070,000.00